News
We bring you up to date at all times: Discover the latest industry news from biotechnology, pharmaceuticals and life sciences. Researched by us so you don't have to.
Selected departments
Selected industries
Companies
The Who's Who of Life Sciences: Discover companies from all over the world. Here you can easily find the provider matching your search, including contact options.
Selected countries
Selected companies
Products
The first stop for your procurement process: discover innovative products for lab and process that make your everyday life easier and solve even complex challenges.
Products of selected companies
White papers
What could be better than an application problem that has already been solved by others? Tap into in-depth application knowledge from proven experts. Conveniently via download to your device.
Most read white papers
White papers of selected companies
Webinars
Exciting lectures and practical application tips via video, whenever you want: Our on-demand webinars make it possible. Make yourself comfortable and click play.
Selected webinars
Webinars of selected companies
Knowledge & education
Question. Answer. Find articles on 57,945 keywords in life science, biotech, pharma, biology and related science disciplines in the encyclopedia..
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Note
The function "Store search" is only available to registered users.
Important information
Currently, you are not logged in to my.bionity.com. Therefore, you can remember a maximum of 5 contents.
FILTER
Refine your search with the following facets to narrow down your results.
29-Nov-2011 - Addex Pharmaceuticals announced that its scientists have demonstrated that, in the presence of GLP-1, glucagon-like-peptide-1 receptor (GLP1R) can form a heterodimer receptor complex with gastric-inhibitory-peptide-receptor (GIPR). The discovery of this novel interaction between the two ...
07-Sep-2011 - Addex Pharmaceuticals announced that it will regain all rights to its metabotropic glutamate receptor 4 (mGluR4) positive allosteric modulator (PAM) program from Merck, known as MSD outside the United States and Canada, due to further pipeline prioritization."We continue to strongly believe that ...
Vincent Lawton appointed to Vice-Chairman
18-Aug-2011 - Addex Pharmaceuticals announced changes to the Company's Board of Directors. Vincent Lawton, an existing director at Addex, has been appointed Vice-Chairman. In addition, Vincent Mutel formally resigned his position as Member of the Board of Directors of Addex. As previously announced, Dr. Mutel ...
17-Aug-2011 - Addex Pharmaceuticals announced the appointment of Dr Bharatt Chowrira as its Chief Executive Officer. Dr Chowrira has a strong track record in the biopharmaceutical industry with over 17-years of experience, combining a unique blend of research, licensing, corporate development, operations and ...
07-Jun-2011 - Addex Pharmaceuticals Ltd announced that Vincent Mutel, PhD, has stepped down from his position as CEO of the Addex group. Mr. André J. Mueller, chairman of the board of Addex, will act as executive chairman and lead an operational subcommittee of directors to manage the transition until a new ...
02-May-2011 - Addex Pharmaceuticals Ltd announced that its shareholders approved all the proposals of the board of directors at its 2011 annual general meeting (AGM). Hoyoung Huh and Oleg Nodelman have joined the board of directors while Beat Lüthi resigned.Dr. Hoyoung Huh has been involved in the formation ...
Second Phase IIa trial to begin this quarter with Addex allosteric modulators
06-Apr-2011 - Addex Pharmaceuticals announced the initiation of a Phase IIa clinical trial to evaluate dipraglurant in patients with Parkinson's disease levodopa-induced dyskinesia (PD-LID), a debilitating movement disorder caused by long-term treatment with levodopa, the gold standard therapy for Parkinson's ...
05-Apr-2011 - Addex Pharmaceuticals announced the start of a Phase IIa clinical trial of ADX71149 for the treatment of schizophrenia. ADX71149, a positive allosteric modulator (PAM) of metabotropic glutamate receptor 2 (mGluR2), is the result of a successful discovery collaboration and licensing deal announced ...
13-Dec-2010 - At EuropaBio’s event on Innovation in Biotechnology, Addex Pharmaceuticals was revealed as the winner of EuropaBio’s Most Innovative European Biotech SME Award before an audience of EU regulators, CEOs, VCs, stakeholders, industry representatives and journalists. Addex triumphed as winners over ...
10-Sep-2010 - Addex Pharmaceuticals Ltd announced that it has been awarded a $900,000 grant from the Michael J. Fox Foundation (MJFF) to help fund a Phase II study of ADX48621 for the treatment of Parkinson’s disease levodopa-induced dyskinesia (PD-LID). Patients with PD can live 10-20 years after diagnosis; ...
© 1997-2024 LUMITOS AG, All rights reserved